Role of afatinib in the treatment of advanced lung squamous cell carcinoma - PubMed (original) (raw)

Review

Role of afatinib in the treatment of advanced lung squamous cell carcinoma

Tiziana Vavalà. Clin Pharmacol. 2017.

Abstract

Lung cancer treatment has considerably changed over the last few years: the identification of druggable oncogenic alterations and innovative immunotherapic approaches granted lung cancer patients the possibility of more efficient and less toxic therapeutic options than chemotherapy. Nowadays, lung squamous cell carcinomas (SqCCs) patients have the chance to benefit from novel treatment alternatives, including immune checkpoint blockade and anti-angiogenic agents and, given positive trial results, from afatinib, a second generation tyrosine kinase inhibitor (TKI) that irreversibly antagonizes ErbB family tyrosine kinase receptors. Considering the role of the ErbB-signaling cascade in lung SqCC, it is relevant to note that ErbB1 (epidermal growth factor receptor [EGFR]) is overexpressed in 85% of non-small-cell lung carcinomas (NSCLCs), particularly in patients with squamous histology, and is associated with poor prognosis. For this reason, EGFR activity has been investigated as a therapeutic strategy in lung SqCC. Even taking into account statistically positive trial results, anti-EGFR approach still remains controversial in unselected/wild-type EGFR lung SqCC patients, as well as the optimal timing and sequencing of all available targeted therapies considering the approval of immunotherapeutic agents. This review analyzes current data about EGFR inhibition in lung SqCC with a specific focus on afatinib in order to elucidate available clinical evidence supporting EGFR targeting in this setting as well as a future management of advanced lung SqCCs in the context of new emerging immunotherapeutic drugs.

Keywords: EGFR; LUX-Lung; NSCLC; TKI; lung cancer; tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

Disclosure The author reports no conflicts of interest in this work.

Similar articles

Cited by

References

    1. WHO Statistics.int [webpage on the Internet] [Accessed July 21, 2017]. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/
    1. Travis WD. Pathology of lung cancer. Clin Chest Med. 2011;32:669–692. - PubMed
    1. Vavalà T, Novello S. SC10.04 second-line therapy and beyond in squamous cell NSCLC. J Thorac Oncol. 2017;12(1):S101–S102.
    1. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21(20):3798–3807. - PubMed
    1. López-Malpartida AV, Ludeña MD, Varela G, García Pichel J. Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas. Lung Cancer. 2009;65(1):25–33. - PubMed

Publication types

LinkOut - more resources